Portola Pharmaceuticals Inc. buy stratec
Summary
This prediction ended on 13.01.20 with a price of €13.20. The prediction for Portola Pharmaceuticals Inc. disappointed with a performance of -26.56%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Portola Pharmaceuticals Inc. | 0.012% | 0.012% | -32.057% | -67.867% |
| iShares Core DAX® | 1.080% | -2.131% | 14.264% | 15.290% |
| iShares Nasdaq 100 | 0.362% | 7.059% | 35.383% | 56.103% |
| iShares Nikkei 225® | -1.155% | -0.483% | 8.258% | 4.324% |
| iShares S&P 500 | 0.806% | 5.037% | 29.635% | 49.529% |
Comments by stratec for this prediction
In the thread Portola Pharmaceuticals Inc. diskutieren
Portola's two approved drugs are targeting significant markets:
The most important of these is Andexxa.
This compound is targeted at being a "universal antidote" for the new breed of anticoagulants like Eliquis. This is something the industry has desperately needed for some time, as more than 80,000 individuals end up in the emergency room annually in the United States due to negative reactions to these medications, many of them life threatening. Andexxa was just approved in May of this year and is just being rolled out. The second generation Andexxa should be approved at yearend. The first
generation is only being marketed to select hospitals. Approval of the second generation Andexxa will kick manufacturing and marketing of Andexxa into overdrive.
The other compound in Portola's product portfolio is Bevyxxa or betrixaban which was approved for Venous thromboembolism (VTE) Prevention in the early summer of 2017. To be more specific, Bevyxxa is the only FDA approved drug for VTE in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complication due to moderate or severe restricted mobility and other risk factors for VTE.
The company has another promising compound 'Cerdulatinib' in development. Cerdulatinib has been granted the Orphan Drug Designation by the FDA for the treatment of peripheral T-cell lymphoma. A pivotal trial for this condition should kick off in the first quarter of next year. Updated Phase 2 data for the treatment of refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer will be presented at the big American Society of Hematology or ASH conference on December 3rd.
Stopped prediction by stratec for Portola Pharmaceuticals Inc.
Portola Pharmaceuticals Inc.
26.12.17
21.02.18
21.02.18
